Azerbaijan vs Euro area: Access to anti-retroviral drugs, female
Azerbaijan
98.0%
in 2024
Euro area
88.6%
in 2022
Azerbaijan rank
1st
Euro area rank
2nd
Access to anti-retroviral drugs, female over time
- Azerbaijan
- Euro area
How they compare
Azerbaijan currently reports 98.0% against 88.6% in Euro area, a difference of 9.4%.
That makes Azerbaijan's figure about 1.1 times Euro area's.
Across all 22 years both countries report, Euro area has been ahead every year.
Azerbaijan ranks 1st and Euro area ranks 2nd of 141 countries.
Euro area has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Azerbaijan | Euro area | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.0% | 59.0% | 58.0% | Euro area |
| 2010s | 32.0% | 81.4% | 49.4% | Euro area |
| 2020s | 77.0% | 87.5% | 10.5% | Euro area |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Azerbaijan or Euro area?
- Azerbaijan, at 98.0% against 88.6% in Euro area as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Azerbaijan and Euro area?
- 9.4%, with Azerbaijan ahead.
- How many years of comparable data are there for Azerbaijan and Euro area?
- 22 years are reported by both, from 2000 to 2022.
- How do Azerbaijan and Euro area rank globally for access to anti-retroviral drugs, female?
- Azerbaijan ranks 1st and Euro area ranks 2nd of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.